FDA Moves to Permanently Close 503B Compounding of Tirzepatide
Released: Last reviewed:
The FDA has proposed to permanently strip tirzepatide of the last legal pathway for large-scale compounding. Here is what changed, where the decision stands, and what it means for patients.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
On April 30, 2026, the FDA proposed to permanently exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk. The public comment period closed June 29, 2026, and a final determination is pending as of July 9, 2026. If finalized, it would end large-scale 503B compounding of these GLP-1 drugs even during a future shortage. Patient-specific 503A compounding with documented medical need is not eliminated.
What the FDA proposed
Outsourcing facilities may generally compound from a bulk drug substance only when that substance is on the 503B bulks list or the finished drug is on the FDA shortage list. With tirzepatide off the shortage list since December 2024, bulks-list inclusion was the last remaining pathway. The agency reviewed the nominations and concluded these three molecules do not belong on the list, and explicitly declined to treat affordability or insurance access as a qualifying clinical need.
How the regulatory timeline unfolded
| Date | Action |
|---|---|
| Oct 2 / Dec 19, 2024 | FDA declares the tirzepatide shortage resolved |
| Feb 18, 2025 | 503A enforcement discretion for tirzepatide ends |
| Mar 19, 2025 | 503B enforcement discretion for tirzepatide ends |
| Apr 30, 2026 | FDA proposes excluding tirzepatide/semaglutide/liraglutide from the 503B bulks list |
| Jun 29, 2026 | Public comment period closes; final determination pending |
Sources: FDA drug-shortage statements and the April 30, 2026 FDA press announcement.
Why compounding boomed — and why cost is the flashpoint
The economics explain the stakes. During the shortage, compounded tirzepatide typically cost a fraction of the brand price, which is why a large telehealth market formed around it. The FDA’s position is that price alone is not a clinical justification once an FDA-approved product is available.
What changes and what does not
| Pathway | Status after a final rule |
|---|---|
| 503B outsourcing (bulk) | Foreclosed for tirzepatide/semaglutide/liraglutide |
| 503A patient-specific | Remains lawful with documented medical necessity |
| Brand Mounjaro / Zepbound | Unaffected; FDA-approved and widely available |
| Compounded FDA-approval status | Unchanged — compounded remains not FDA-approved |
What patients should do now
Ask any provider which pharmacy pathway it uses, how it is adapting to the 2026 rules, and how it documents the clinical basis for each prescription. For deeper background, see our 503B bulks-list explainer, post-shortage access guide, and 503A vs 503B comparison.
What the comment period debated
The public docket drew sharply divided input. Compounding and telehealth groups argued that access and affordability constitute a real patient need and warned that removing the pathway would strand people who cannot afford brand pricing. Manufacturers and patient-safety advocates countered that FDA-approved products are now available, that copies bypass the approval process, and that the statute defines “clinical need” narrowly — excluding price. The FDA’s proposal sided with the latter reading, which is why a final rule, if it mirrors the proposal, would be difficult to reverse without new legislation or a fresh shortage designation.
How to read the final rule when it lands
When the FDA publishes its final determination, three things will matter most for patients: whether the exclusion is adopted as proposed, whether any carve-outs are added for specific dosage forms or documented allergies, and the effective date. Watch the Federal Register and the FDA’s compounding pages rather than clinic blogs, which sometimes lag or overstate. Until a final rule publishes, the proposal is exactly that — a proposal — and 503A patient-specific compounding continues under existing rules.
Frequently asked questions
Is compounded tirzepatide banned now? No. The proposal targets large-scale 503B bulk compounding. Patient-specific 503A compounding with a documented clinical need remains lawful, and brand tirzepatide is unaffected.
When could the rule become final? The public comment period closed June 29, 2026. The FDA will weigh comments before a final determination; as of July 9, 2026 no final rule has published.
Why did compounded tirzepatide get so popular? During the 2022–2024 shortage, compounded vials sold for roughly $150–$300 a month versus more than $1,000 for brand pens, and telehealth made access frictionless.
Does a future shortage reopen compounding? If finalized as written, the exclusion would foreclose the 503B bulk pathway even if a new shortage were declared — a key reason the proposal matters.
July 9, 2026: Published; confirmed comment period closed June 29, 2026 with a final rule pending.
April 30, 2026: FDA published the 503B bulks-list exclusion proposal.
Sources
- FDA — Proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — April 30, 2026
- FDA — Compounder policy update as GLP-1 supply stabilizes
- Pharmacy Times — FDA moves to permanently close the door on compounded GLP-1s
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.